StockNews.AISignal intelligence
Shattuck Labs, Inc. · NASDAQ · Healthcare
Browse public STTK signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Shattuck Labs reported positive Phase 1 data for SL-325, a DR3-targeting antibody for inflammatory bowel disease, with favorable safety and occupancy supporting a Phase 2b in 3Q2026. The stock trades near $4.86 with an RSI of 24.1, indicating oversold conditions and potential near-term rebound if data translate into clinical progress. Analysts have raised price targets, signaling longer-term upside.
View signal analysisHC Wainwright upgraded STTK to Buy with a $6 price forecast. Shattuck's SL-325 targets DR3 for IBD, potentially capturing market share. First healthy participants dosed in Phase 1 trial in Q3 2025. Competitors face issues with immunogenicity and durability of response. STTK stock increased 13.3% to $2.38 following the upgrade.
View signal analysisShattuck Labs discontinued SL-172154 development due to limited efficacy. Stock fell 45% following the announcement, impacting investor confidence. Collaboration with Ono Pharmaceutical was terminated, limiting future income. Future focus is on SL-325 for inflammatory bowel disease clinical development. Company plans to reduce workforce by 40% to streamline operations.
View signal analysisShattuck Labs Inc. stock fell 43% after scrapping main product candidate. Company to cut 40% of its staff as part of restructuring. Termination of license agreement with Ono Pharmaceutical causes further investor concern. Stock is down 72% year-to-date versus biotech ETFs gaining 6-8%. Previous high price of $60.52 contrasts sharply with current low of $1.37.
View signal analysis